Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892075 | 0.74 | NOTUM (0.59) | NOTUMF2MEN1KMT2AMAPT | |
| SCHEMBL1197728 | 0.74 | NOTUM (0.55) | NOTUMF2MEN1KMT2AMAPT | |
| SCHEMBL184324 | 0.73 | NOTUM (0.52) | NOTUMF2KMT2AMAPTLMNA | |
| SCHEMBL3819681 | 0.71 | NOTUM (0.61) | NOTUMF2MEN1KMT2ALMNA | |
| SCHEMBL9872640 | 0.70 | CYP19A1 (0.35) | — | |
| SCHEMBL11117017 | 0.68 | NOTUM (0.56) | NOTUMF2MEN1KMT2A | |
| SCHEMBL16054650 | 0.67 | — | — | |
| SCHEMBL23466554 | 0.66 | NOTUM (0.53) | NOTUMF2KMT2ALMNA | |
| SCHEMBL3009848 | 0.66 | NOTUM (0.53) | NOTUMF2MEN1KMT2AMAPT | |
| SCHEMBL1460681 | 0.66 | NOTUM (0.53) | NOTUMF2KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959516-A | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2011-01-26 | — | — | CN | disclosed |